Affiliation:
1. Health Sciences University
2. Health Sciences University, Yuksek Ihtisas Training and Research Hospital
Abstract
Abstract
Aim
In resistant infections and septic patients, the choice of colistin in the selection of antibiotic therapy is important in the treatment response. Kidney damage is common after antibiotic use. In our study, we evaluated the clinical and laboratory data of the patients who developed nephrotoxicity after the use of colistin, followed in the intensive care unit of our hospital.
Material and Methods
The clinical and laboratory characteristics and treatment results of 148 patients (54 nephrotoxic patients) with infection who were followed up in the intensive care unit (ICU) of our hospital evaluated.
Results
The group that developed nephrotoxicity was older [70.5 (40–91), p < 0.001]. The APACHE II score was higher in the nephrotoxicity group [20.5 (5–49), p = 0.004]. Positive inotrope use and mortality were higher in the nephrotoxicity group [32 (59.3%), p < 0.001 and 30 (55.6%), p = 0.004]. The duration of colistin use was longer in the nephrotoxicity group [13.5 (3–36), p = 0.045]. In the group that developed nephrotoxicity, the highest growth was detected in the tracheal aspirate (TAS) [49 (90.7%), p = 0.045]. Positive inotrope use and growth in TAS culture predisposed the development of nephrotoxicity in multivariate analysis [3.12 (1.38–7.02), CI 95%, p = 0.006, 5.70 (1.64–19.79), CI 95%, p = 0.006].
Conclusion
Consideration should be given to the use of colistin in resistant infections and septic patients in terms of nephrotoxicity and mortality. Antibiotic selection should be considered in critically ill patients, and patients should be closely monitored.
Publisher
Research Square Platform LLC
Reference19 articles.
1. El-Sayed Ahmed MAE, Zhong LL, Shen C, Yang Y, Doi Y, Tian GB. Colistin and its role in the Era of antibiotic resistance: an extended review (2000–2019). Emerg Microbes Infect., Tran TB, Velkov T, Nation RL, Forrest A, Tsuji BT, Bergen PJ, Li J. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet? Int J Antimicrob Agents. 2016;48(6):592-7.
2. Colistin: an antibiotic and its role in multiresistant Gram-negative infections;Loho T;Acta Med Indones,2015
3. Risk factors for colistin-associated nephrotoxicity and mortality in critically ill patients;Özkarakaş H;Turk J Med Sci,2017
4. Polymyxin Acute Kidney Injury: Dosing and Other Strategies to Reduce Toxicity;Nation RL;Antibiot (Basel),2019
5. Acute kidney injury: taking aim at colistin;Rashid S;Crit Care,2014